vgsc blocker1

(+)-KCC2 blocker 1 is a selective blocker of KCC2 (IC50 = 0.4 μM).

DMT1 blocker 1 is a blocker of divalent metal transporter 1 (DMT1) with IC50 of 0.64 μM, which is expected to block the absorption of iron by intestinal cells in vivo.

TRPV2-selective blocker 1 (compound IV2-1) is a selective inhibitor of the TRPV2 channel, exhibiting an IC50 value of 6.3 μM. It specifically targets the TRPV2 channel without impacting related TRPV1, TRPV3, or TRPV4 channels. Additionally, this compound effectively suppresses TRPV2-mediated calcium influx in macrophages and inhibits their phagocytic activity [1].

VGSC blocker-1 is a powerful small molecule that serves as a blocker for the neonatal isoform of the VGSC subtype known as Nav1.5 (nNav1.5). It effectively blocks INa peak currents by 34.9% at a concentration of 1 μM, and demonstrates a 0.3% inhibition of cell invasion at the same concentration in the MDA-MB-231 human breast cancer cell line, without compromising cell viability.

N-type calcium channel blocker-1 is an orally active analgesic agent,shows high affinity to functionally block N-type calcium channels.

MTDH-SND1 Blocker 1 (Compound C26-A6) serves as an inhibitor targeting the MTDH-SND1 protein, effectively suppressing cancer metastasis [1].

Cav 2.2/3.2 blocker 1 (Compound 9e) is a neuronal calcium channel blocker that acts on Cav2.2 (IC50: 1.22 μM) and Cav3.2 (IC50: 80 μM). Can penetrate the central nervous system.

NaV1.2/1.6 channel blocker-1 is a potent NaV1.2/1.6 channel blocker with inhibitory effects on rNaV1.6 and hNaV1.2.NaV1.2 channel blocker-1 can be used in the study of generalised epilepsy and movement disorders.

Cav 2.2 blocker 1 is an N-type calcium channel (Cav 2.2; IC50: 1 nM) blocker for the treatment of pain.